Rigrodsky & Long, P.A. announces that it has launched an investigation on behalf of the shareholders of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) (Nasdaq: PACB) for possible violations of the Federal securities laws.

If you are a PACB shareholder who purchased your stock pursuant or traceable to the Company’s Initial Public Offering on October 27, 2010 (the “IPO”) or purchased PACB common stock between October 27, 2010 and September 21, 2011 and would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Timothy J. MacFall, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com,or at: http://investigations.rigrodskylong.com/pacific-biosciences-of-california-inc-pacb/.

PACB is a development stage company that develops, manufactures, and markets an integrated platform for genetic analysis. The Company engages in commercializing a platform, single molecule, real-time technology (SMRT) for the detection of biological events.

The investigation surrounds the Company’s failure to disclose in connection with its IPO that, contrary to the PACB’s claim that its RS system had a 99.99% base calling accuracy rate, the RS’s raw-read accuracy rate was only 80%-84% such that would-be customers would have to sacrifice long read length to obtain increased raw-read accuracy, that countless insidious bugs in the RS system caused it to be highly unreliable and crash often, and that significant negative feedback had been received from limited production users of the system.

On August 5, 2011, J.P. Morgan issued a report cutting PACB’s rating from Overweight to Neutral, stating that due to a slower ramp-up in orders now being expected it was “lowering [its] 2012 projection from systems recognized from 170 to 90” and is now “not forecast[ing] operating profitability until after 2015.” In reaction to this news, PACB stock plunged 34% to close at $6.50 per share on August 5, 2011.

If you liked this article you might like

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Health Sector Down As Report of Industry Price Collusion Surfaces

Illumina Shares Hammered by Sales Forecast Cut